Výsledky vyhledávání - "Margit Janat-Amsbury"

P11.02 Targeting the Tumor Neovasculature in Lung Cancer: A Phase I Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer

Autor: Aditya Shetty, Mark Salvati, George R. Blumenschein, S. Tiso, Hosein Kouros-Mehr, T. Eggert, Margit Janat-Amsbury, V. Gupta, A.S. Bhatia, Michael Boyer

Publikováno v: Journal of Thoracic Oncology. 16:S1006

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9bd38f8b356eb2355f481642b71d57ee
https://doi.org/10.1016/j.jtho.2021.08.321

Zobrazit plný text záznamu

Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC)

Autor: Camila Jhones, Joseph Maly, Lakshminarayanan Nandagopal, Sumit K. Subudhi, Freda Cooner, Andrew Paluch, Young E. Whang, Anthony M. Joshua, Mark Salvati, Hosein Kouros-Mehr, Vinita Gupta, Rahul Aggarwal, Xianne Penny, Mukul Minocha, Johann S. de Bono, Bilal A. Siddiqui, Tobias Eggert, Margit Janat-Amsbury, Elaine T. Lam

Publikováno v: Journal of Clinical Oncology. 39:TPS5088-TPS5088

TPS5088 Background: Lesions in mCRPC are typically immunologically cold. AMG 160 binds to PSMA on cancer cells and CD3 on T cells, leading to T-cell infiltration, activation, expansion, and tumor cell killing. In a first-in-human study, AMG 160 has d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b84c95121e226a12e008d314b133e9e3
https://doi.org/10.1200/jco.2021.39.15_suppl.tps5088

Zobrazit plný text záznamu

A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654 administered daily for 28 days to patients with advanced solid tumors

Autor: Clifford J. Whatcott, Steven L. Warner, Mark Wade, Margit Janat-Amsbury, Lars Mouritsen, Patrick M. Dillon, Ignacio Garrido-Laguna, Stephen P. Anthony, Siqing Fu, Nissa Ashenbramer, David J. Bearss

Publikováno v: Journal of Clinical Oncology. 38:3586-3586

3586 Background: TP-3654 is an oral, second generation, potent PIM-1 kinase inhibitor with activity against PIM 2, 3 and favorable selectivity against other kinases. These cytoplasmic serine/threonine kinases are highly expressed in many cancers and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3a924135a7eaf80d64df4f717d1e9d37
https://doi.org/10.1200/jco.2020.38.15_suppl.3586

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání